The First Affiliated Hospital of Xinxiang Medical College
Phase
Not applicable
Started
2025-08-15
Last updated
2025-08-22
Condition(s) studied
Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition)
Investigational drug(s) / intervention(s)
AI-assisted comprehensive management system
AI-assisted comprehensive management system: Precision Risk Stratification and personalized treatment recommendation through AI models may improve the suitability of treatment regimens and thus reduce the incidence of antineoplastic therapy-related adverse effects (e.g. , reduction of chemotherapy toxicity through nutritional intervention) , and improve the efficacy of chemotherapy, and prolonged progression-free survival (PFS) and overall survival (OS)
Study summary
Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with a definite diagnosis of malignancy by histopathology and/or cytology;
* Age ≥18 years;
* There is no gender limit
* Plan to receive antineoplastic therapy within 2 weeks or are receiving standard antineoplastic care (surgery, radiation, chemotherapy, or targeted therapy) ;
* Conscious and able to answer questions and use electronic devices autonomously;
* Patients were able to understand the study and voluntarily sign an informed consent form;
Exclusion Criteria:
* Having severe mental or cognitive impairments that prevent them from understanding the content of the study or implementing the programme;
* With severe heart disease, acute respiratory failure, liver kidney failure and other critical illness;
* Women during pregnancy or lactation；
* Have participated in other interventional studies in the past 1 month or are currently participating;
* Patients with ECOG ≥ 3 that do not respond to treatment;
* Patients with an expected survival of \< 3 months that do not respond to treatment;
* Cases deemed unsuitable for enrollment by the investigator.
Primary outcome measure(s)
Progression-free survival (PFS) — 24 months Progression-free survival (PFS) : the time from randomization (or study enrollment) to the observation of disease progression or the occurrence of death from any cause. This period was assessed every 6-8 weeks using RECIST 1.1 criteria.
Overall survival (OS） — 24 months Overall survival (OS） : the time from study enrollment to death from any cause from any cause, every 3 months during treatment, and every 3 months after the end of treatment. The patients were followed up at 6 months and the cause of death was recorded.
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang
Henan
More The First Affiliated Hospital of Xinxiang Medical College trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.